TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36350359

Group type: EXPERIMENTAL
Intervention: Vitamin D intake from supplements
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Consumption of milk products
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Consumption of meat products
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Travels to sunny countries
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Average daylight time
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Total vitamin D intake from food and supplements
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (S-25(OH)D) levels
Number of subjects: 265
Study: 36350362

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36350468

Group type: EXPERIMENTAL
Intervention: Recent onset dyspnoea (< 24 h)
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Chest pain
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Pleuritic pain
Number of subjects: 1365

Group type: EXPERIMENTAL
Intervention: Phlebitis
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Asymptomatic
Number of subjects: 1365
Study: 36350598

Group type: EXPERIMENTAL
Intervention: Treatment for Alcohol Use Disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 36350899

Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Number of subjects: 15

Group type: COMPARATOR
Intervention: cabazitaxel chemotherapy
Number of subjects: 15
Study: 36350983

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 36351064

Group type: EXPERIMENTAL
Intervention: Welch Allyn Connex® Spot Monitor/Hillrom Connecta™ automated solution
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual routine (manual activation)
Number of subjects: 216
Study: 36351188

Group type: EXPERIMENTAL
Intervention: Targeted verifiable subcision (TVS) using the Avéli device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 0
Study: 36351402

Group type: EXPERIMENTAL
Intervention: Platelet-specific p110β deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic inhibition of p110β with TGX-221
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet p110β
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic deficiency or inhibition of platelet p110β
Number of subjects: 0
Study: 36351430

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma (CCP) therapy
Number of subjects: 0
Study: 36351712

Group type: EXPERIMENTAL
Intervention: Women with myocardial infarction
Number of subjects: 9551

Group type: COMPARATOR
Intervention: Men with myocardial infarction
Number of subjects: 9551
Study: 36351716

Group type: EXPERIMENTAL
Intervention: MRI by advanced MRI techniques (diffusion tensor, cerebral perfusion, functional MRI, cerebral volumetry and cortical thickness, spectroscopy, susceptibility imaging)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-level athletes not exposed to head impacts
Number of subjects: 0
Study: 36351728

Group type: EXPERIMENTAL
Intervention: Remifentanil dose titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36351741

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 30 mL 2.5 mg/mL ropivacaine and 0.3 mL gadolinium.
Number of subjects: 10
Study: 36351814

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) and/or endovascular treatment (EVT)
Number of subjects: 15
Study: 36351919

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with severe Neuro-COVID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 patients with plasma cytokine storm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-acute COVID-19 syndrome patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 0
Study: 36351931

Group type: EXPERIMENTAL
Intervention: CoVLP+AS03 vaccine (3.75 µg CoVLP/dose + AS03), administered as two intramuscular doses, 21 days apart.
Number of subjects: 753
Study: 36352028

Group type: EXPERIMENTAL
Intervention: AZD8931 (160 mg bd) with FOLFIRI
Number of subjects: 18
Study: 36352054

Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg single oral dose
Number of subjects: 17

Group type: COMPARATOR
Intervention: Matched healthy subjects (n=8 after one subject discontinued)
Number of subjects: 17
Study: 36352103

Group type: EXPERIMENTAL
Intervention: 1 mL t.i.d. treatment with a full-spectrum, high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL Δ-9-tetrahydrocannabinol)
Number of subjects: 14
Study: 36352322

Group type: EXPERIMENTAL
Intervention: CT/NG screening program offered annually from January 2018
Number of subjects: 234
Study: 36352423

Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) during resting breathing
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) during forced expiration
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 33

Group type: COMPARATOR
Intervention: PFT (Pulmonary Function Tests), FENO, IOS
Number of subjects: 33
Study: 36352455

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) combined with ruxolitinib
Number of subjects: 21
Study: 36353027

Group type: EXPERIMENTAL
Intervention: Cognitive behavior sex therapy (CBST)
Number of subjects: 0
Study: 36353230

Group type: EXPERIMENTAL
Intervention: Obesity assessed by body mass index (BMI)
Number of subjects: 0
Study: 36353571

Group type: EXPERIMENTAL
Intervention: Cenegermin
Number of subjects: 5
Study: 36353661

Group type: EXPERIMENTAL
Intervention: abiraterone acetate plus prednisone (ABI-DOCE)
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: docetaxel (DOCE)
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: enzalutamide (ENZA)
Number of subjects: 3003

Group type: EXPERIMENTAL
Intervention: Various treatment sequences including ABI-DOCE, ABI-ENZA, ABI-RAD, DOCE-ABI, DOCE-CABA, DOCE-ENZA, ENZA-DOCE
Number of subjects: 3003

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3003
Study: 36353697

Group type: EXPERIMENTAL
Intervention: haMSter app for monitoring patient reported outcomes (PROs)
Number of subjects: 50
Study: 36354082

Group type: EXPERIMENTAL
Intervention: FB2001
Number of subjects: 0
Study: 36355054

Group type: EXPERIMENTAL
Intervention: AZD8205 (3.5 mg/kg single administration)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: AZD5305 (in combination with AZD8205)
Number of subjects: 26
Study: 36355259

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with Tumor Treating Fields (TTFields, 200 kHz), standard concurrent temozolomide (TMZ), and scalp-sparing radiation (60 Gy in 30 fractions). Maintenance therapy included standard TMZ and continuation of TTFields.
Number of subjects: 30
Study: 36355406

Group type: EXPERIMENTAL
Intervention: Web-based intervention (9-module course comprising psychoeducation and home practice)
Number of subjects: 1754

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1754
Study: 36355613

Group type: EXPERIMENTAL
Intervention: Chronic Hypertension (cHTN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normotensive Gravidas
Number of subjects: 100
Study: 36355639

Group type: EXPERIMENTAL
Intervention: Psychological intervention designed to increase PAP adherence delivered via telehealth.
Number of subjects: 17
Study: 36355650

Group type: EXPERIMENTAL
Intervention: Parent involvement CBT targeting negative reinforcement
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Parent involvement CBT targeting psychological control
Number of subjects: 211

Group type: COMPARATOR
Intervention: Individual-youth CBT
Number of subjects: 211
Study: 36355684

Group type: EXPERIMENTAL
Intervention: Vaping as usual
Number of subjects: 30

Group type: COMPARATOR
Intervention: Short-term nicotine deprivation (16 hr)
Number of subjects: 30
Study: 36355754

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort
Number of subjects: 157134
Study: 36355775

Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine (two immunizations)
Number of subjects: 3
Study: 36356042

Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 36356184

Group type: EXPERIMENTAL
Intervention: Screening modality (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast density (not specified)
Number of subjects: 0
Study: 36356235

Group type: EXPERIMENTAL
Intervention: Supine orthostatic hypotension assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seated orthostatic hypotension assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Falls and orthostatic symptoms
Number of subjects: 0
Study: 36356418

Group type: EXPERIMENTAL
Intervention: Internal mammary chain radiation therapy (RT)
Number of subjects: 3295

Group type: EXPERIMENTAL
Intervention: Normofractionated radiation therapy (RT)
Number of subjects: 3295
Study: 36356599

Group type: EXPERIMENTAL
Intervention: Non-viral precision T cell receptor replacement
Number of subjects: 0
Study: 36356684

Group type: EXPERIMENTAL
Intervention: Baveno VII algorithm with SSM@50 Hz
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Baveno VII algorithm with SSM@100 Hz
Number of subjects: 504

Group type: COMPARATOR
Intervention: Other measures (LSM-longitudinal spleen diameter to platelet ratio score)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Other measures (platelet count/longitudinal spleen diameter ratio)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Other measures (Rete Sicilia Selezione Terapia-hepatitis)
Number of subjects: 504
Study: 36356712

Group type: EXPERIMENTAL
Intervention: dupilumab/dupilumab
Number of subjects: 1530

Group type: COMPARATOR
Intervention: placebo/dupilumab
Number of subjects: 1530
Study: 36356959

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 168
Study: 36356972

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 80 mg as a continuous daily infusion for 8 days followed by slow tapering
Number of subjects: 677

Group type: COMPARATOR
Intervention: Conventional dexamethasone (6 mg daily for 7-10 days)
Number of subjects: 677
Study: 36357018

Group type: EXPERIMENTAL
Intervention: Amulet device
Number of subjects: 1833

Group type: COMPARATOR
Intervention: Watchman device
Number of subjects: 1833
Study: 36357087

Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 3077
Study: 36357133

Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden above the median
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: GRACE score >140
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Obstructive coronary artery disease
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Total plaque burden
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Noncalcified plaque burden
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Low-attenuation plaque burden
Number of subjects: 404
Study: 36357295

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) therapy
Number of subjects: 36
Study: 36357392

Group type: EXPERIMENTAL
Intervention: Branaplam (splicing modulator)
Number of subjects: 0
Study: 36357415

Group type: EXPERIMENTAL
Intervention: Neoadjuvant camrelizumab plus concurrent chemoradiotherapy
Number of subjects: 36
Study: 36357790

Group type: EXPERIMENTAL
Intervention: Non-operative management (initial strategy in 152 patients, 48.1%)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Urgent surgery (performed in 164 patients, 51.9%)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 316
Study: 36357877

Group type: EXPERIMENTAL
Intervention: PrEP awareness influenced by external factors such as social media and community knowledge about HIV treatment and prevention.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Joining the HIV vaccine trial preparedness study.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Community perceptions of PrEP usage.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Understanding barriers to PrEP uptake.
Number of subjects: 25
Study: 36357881

Group type: EXPERIMENTAL
Intervention: MINDxYOU online intervention
Number of subjects: 180
Study: 36357934

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic targeting symptom management through a trigger alert system, utilizing electronic patient-reported outcome (ePRO) assessments at baseline, and 2, 4, 6, 8, 10, and 12 months, including input from a dietitian monitoring diet and nutritional status.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care pathway standard of care, attending the cancer survivorship clinic and completing ePRO assessments at the start and end of the study.
Number of subjects: 200
Study: 36357949

Group type: EXPERIMENTAL
Intervention: Giving birth during the pandemic
Number of subjects: 12133

Group type: COMPARATOR
Intervention: Giving birth before the pandemic
Number of subjects: 12133
Study: 36358012

Group type: EXPERIMENTAL
Intervention: VPM1002
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study: 36358277

Group type: EXPERIMENTAL
Intervention: Comprehensive immune age metric
Number of subjects: 597

Group type: COMPARATOR
Intervention: Chronological age
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Obesity and physical activity
Number of subjects: 597
Study: 36358642

Group type: EXPERIMENTAL
Intervention: Automated method (AM) for calculating metabolic tumor volume (MTV)
Number of subjects: 100
Study: 36358694

Group type: EXPERIMENTAL
Intervention: Pre-emptive Lymphocytes-apheresis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard-of-care Lymphocytes-apheresis
Number of subjects: 14
Study: 36358702

Group type: EXPERIMENTAL
Intervention: Calcium electroporation (CaEP) with intratumoral injection of calcium gluconate followed by reversible electroporation.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Calcium electroporation (CaEP) treatment.
Number of subjects: 8
Study: 36358930

Group type: EXPERIMENTAL
Intervention: Tirzepatide (TRZD), a GLP-1 and GIP agonist, used as an anti-diabetic drug.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anti-diabetic/glucose-lowering drugs (general category).
Number of subjects: 0
Study: 36360424

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Polytherapy
Number of subjects: 159
Study: 36360619

Group type: COMPARATOR
Intervention: Push-ups on stable surface (PS)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Push-ups on monopodal surface (PM)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Push-ups on rings (PR)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Push-ups on TRX
Number of subjects: 51
Study: 36360766

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy sleep programme sessions (2 sessions)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 60
Study: 36361102

Group type: EXPERIMENTAL
Intervention: Athens Insomnia Scale (AIS)
Number of subjects: 200
Study: 36362554

Group type: EXPERIMENTAL
Intervention: Low Barthel index
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Low grip strength
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Low physical activity level
Number of subjects: 355
Study: 36362599

Group type: EXPERIMENTAL
Intervention: Supraglottic airway devices (SGA)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 343
Study: 36362730

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) in non-calcific aortic stenosis patients
Number of subjects: 328

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) in calcific aortic stenosis patients
Number of subjects: 328
Study: 36364763

Group type: EXPERIMENTAL
Intervention: Hypertensive individuals
Number of subjects: 989

Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 989
Study: 36366796

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 36367058

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Other antiplatelets
Number of subjects: 66

Group type: COMPARATOR
Intervention: No antiplatelets or poor compliance
Number of subjects: 66
Study: 36367100

Group type: EXPERIMENTAL
Intervention: Reperfusion injury (RORI) observed via imaging after recanalization
Number of subjects: 23
Study: 36367449

Group type: EXPERIMENTAL
Intervention: Twinkle marker
Number of subjects: 8

Group type: COMPARATOR
Intervention: Radioactive seed
Number of subjects: 8

Group type: COMPARATOR
Intervention: Biopsy clip
Number of subjects: 8
Study: 36367600

Group type: EXPERIMENTAL
Intervention: SASP proteins (Activin A, ICAM1, MMP7, VEGFA, eotaxin)
Number of subjects: 1377

Group type: EXPERIMENTAL
Intervention: SASP proteins (PARC, ADAMTS13, RANTES in females; MMP2, SOST, MCP1 in males)
Number of subjects: 1377
Study: 36367717

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine uptake
Number of subjects: 0
Study: 36367759

Group type: EXPERIMENTAL
Intervention: Web-based training course on pediatric palliative care (PPC) for 2 weeks through the Relais Platform.
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care without additional training.
Number of subjects: 172
Study: 36367769

Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (no supervised training)
Number of subjects: 80
Study: 36367894

Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL-PET/CT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Next generation sequencing of tumors
Number of subjects: 50
Study: 36368038

Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Number of subjects: 0
Study: 36368073

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) on two nights
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nights with PSG
Number of subjects: 32

Group type: COMPARATOR
Intervention: Nights without PSG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Comparison of PSG variables between the two PSG nights
Number of subjects: 32
Study: 36368151

Group type: EXPERIMENTAL
Intervention: Non-surgically treated ACL injury
Number of subjects: 125
Study: 36368176

Group type: EXPERIMENTAL
Intervention: Type II diabetes mellitus (T2DM)
Number of subjects: 2002

Group type: COMPARATOR
Intervention: No diabetes mellitus (no-DM)
Number of subjects: 2002
Study: 36368480

Group type: EXPERIMENTAL
Intervention: RT-1 (Recovering Together intervention)
Number of subjects: 194

Group type: COMPARATOR
Intervention: RT-2 (Health education control)
Number of subjects: 194
Study: 36368697

Group type: EXPERIMENTAL
Intervention: Novel venous cannula as part of the EXCOR® VAD for subpulmonary support
Number of subjects: 20
Study: 36368939

Group type: EXPERIMENTAL
Intervention: Prerelese methadone (n=64)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Pre-incarceration alcohol use
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Lower CD4 count
Number of subjects: 291
Study: 36369028

Group type: EXPERIMENTAL
Intervention: TAAR1 agonists
Number of subjects: 0
Study: 36369156

Group type: EXPERIMENTAL
Intervention: Home handheld spirometry
Number of subjects: 0
Study: 36369278

Group type: EXPERIMENTAL
Intervention: Structural heart disease (SHD) patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Myocardial presence of SARS-CoV-2
Number of subjects: 152

Group type: COMPARATOR
Intervention: Myocardial ACE2 expression
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Clinical course of patients with cardiac SARS-CoV-2 manifestation
Number of subjects: 152
Study: 36369401

Group type: EXPERIMENTAL
Intervention: CMV PCR on inner ear fluid
Number of subjects: 113
Study: 36369507

Group type: EXPERIMENTAL
Intervention: Telehealth support comprising automated twice-weekly telephone calls with a specialist nurse triaging alerts.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care without telehealth support (implied control group).
Number of subjects: 0
Study: 36369530

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36369729

Group type: EXPERIMENTAL
Intervention: Mama na Mtoto intervention
Number of subjects: 2070
Study: 36369848

Group type: EXPERIMENTAL
Intervention: EDP-297 20-600 μg single doses
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EDP-297 5-90 μg once daily for 14 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EDP-297 (all doses)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: EDP-297 (60 μg MAD)
Number of subjects: 82
Study: 36370026

Group type: EXPERIMENTAL
Intervention: Higher levels of well-being
Number of subjects: 719
Study: 36370064

Group type: EXPERIMENTAL
Intervention: Haploidentical family (HF) haematopoietic cell transplantation (HCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Matched sibling (MS) haematopoietic cell transplantation (HCT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Unrelated donor (UD) haematopoietic cell transplantation (HCT)
Number of subjects: 101
Study: 36370220

Group type: EXPERIMENTAL
Intervention: Abnormal RVFWLS (> -20%)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Normal RVFWLS (<= -20%)
Number of subjects: 104
Study: 36370226

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 29
Study: 36370233

Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort), one drop per eye every evening
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% ophthalmic solution (FCBT; Ganfort)
Number of subjects: 725
Study: 36370742

Group type: EXPERIMENTAL
Intervention: Olutasidenib monotherapy (150 mg once daily, 150 mg twice per day, 300 mg once daily)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Olutasidenib in combination with azacitidine (75 mg/m2)
Number of subjects: 78